XEN1101 10 mg
XPF-008-204
Phase 2 small_molecule completed
Quick answer
XEN1101 10 mg for Major Depressive Disorder is a Phase 2 program (small_molecule) at Xenon Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xenon Pharmaceuticals
- Indication
- Major Depressive Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed